New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 11, 2020 - Pfizer announced the FDA approval of Nyvepria (pegfilgrastim-apgf), a biosimilar to Amgen’s Neulasta® (pegfilgrastim).
Download PDF
Return to publications
